244 Chapter 11 Table 2. Continued Reference Patients’ Specification No. of Patients for Analysis Tissue Samples Tissue Collection Without PM With PM Schirripa et al. 47 Patients with presence of a KRAS mutation with the focus of the specific variant. 391 108 FFPE tissue from primary tumors and/or paired metastases Not performed, KRAS status was already known Shelygin et al. 35 Patients undergoing surgery for colorectal cancer. 38 20 Tissue samples from primary tumor, peritoneal metastases, and healthy tissue Retrospect, archives of pathology department Shirahata et al. 42 CRC patients who underwent surgery. 47 5 Frozen colorectal cancer tissue and corresponding normal tissues Were collected at surgical resection and stored at the pathology department Shirahata et al. 41 CRC patients who underwent surgery. 43 5 Frozen primary tumor specimens and corresponding normal tissue Were collected at surgical resection and stored at the pathology department Sjo et al. 36 CRC patients with PM. 57 148 * FFPE tumor samples Retrospect, archives of pathology department Smith et al. 37 Patients with measurable metastatic of locally advanced colorectal adenocarcinoma and unresectable disease. 1667 283 FFPE tumor samples (adenocarcinomas) Retrospect, archives of pathology department Takahashi et al. 38 Patients with CRC who underwent surgical treatment. 174 6 Frozen resected tumor samples in liquid nitrogen Retrospect, archives of pathology department Taniguchi et al. 39 Patients with CRC who received any treatment at one of the 15 study hospitals that participated, and who had RAS WT tumors. 62 281 FFPE tumor samples Retrospect, archives of pathology department Tran et al. 48 Patients with mCRC with known BRAF mutation status from two institutional databases. 385 139 Tumor tissue Not performed, BRAF status was already known Yaeger et al. 49 Patients with mCRC with available tumor sequencing. 431 84 FFPE primary tumor samples or metastatic tissue Not performed, BRAF status was already known
RkJQdWJsaXNoZXIy MTk4NDMw